ERT, Bioclinica merger unites clinical trial tech teams

ERT CEO, Joe Eazor, explains to Outsourcing-Pharma how the new organization formed by the merger of ERT and Bioclinica will provide the industry’s most comprehensive endpoint data collection portfolio.

https://www.outsourcing-pharma.com/Article/2021/04/28/ERT-Bioclinica-merger-unites-clinical-trial-tech-teams

Outsourcing Pharma


About ERT

ERT (eResearch Technology) is a global data and technology company that minimizes uncertainty and risk in clinical trials so that its customers can move ahead with confidence. With nearly 50 years of clinical and therapeutic experience, ERT balances knowledge of what works with a vision for what’s next, so it can adapt without compromising standards.

Powered by the company’s EXPERT® technology platform, ERT’s solutions enhance trial oversight, enable site optimization, increase patient engagement and measure the efficacy of new clinical treatments while ensuring patient safety. In 2019, 75% of all FDA drug approvals came from ERT-supported studies. Pharma companies, biotechs, and CROs have relied on ERT solutions across 16,000 studies, spanning more than five million patients to date. By identifying trial risks before they become problems, ERT enables customers to bring clinical treatments to patients quickly ─ and with confidence.

For more information, please visit ert.com or follow us on LinkedIn and Twitter.

ERT Media Contact
Terry Stanulis
Director, Thought Leadership and Public Relations
[email protected]
+1 862-288-0329

Share